Literature DB >> 3028939

Frequency of B-lymphocyte transformation by Epstein-Barr virus decreases with entry into the cell cycle.

A J Roome, C L Reading.   

Abstract

The relationship between in vitro B-cell activation and transformation by Epstein-Barr virus (EBV) was studied. B cells were fractionated using discontinuous Percoll gradients to purify cells with resting morphology. Activation of resting cells for 24 hr with anti-Ig (mu chain specific) or Staphylococcus aureus Cowan I (SAC) resulted in transition of susceptible cells into the G1 phase of the cell cycle as shown by an increase in cell size, an increase in uridine incorporation and an increase in sensitivity to B-cell growth factor (BCGF). Entry into S phase was achieved by extending the period of activation to 48-96 hr with high concentrations of SAC or anti-mu or using BCGF. SAC-activated cells entered S phase on Day 2 and anti-mu treated cells on Day 3. Control (G0) cells and cell activated for varying lengths of time (G0/G1, G1/S) were exposed to EBV and plated in a limiting dilution assay to determine the frequency of EBV-transformable cells. Control cells and cells activated for 24 hr had a transformation frequency of 1-2%. With continued activation with SAC or anti-mu, however, transformation frequency decreased at a rate paralleling the entry of the population into S phase. Treating cells with low concentrations of anti-mu or SAC in combination with BCGF decreased the transformation frequency to levels lower than anti-mu or SAC alone, further suggesting that entry into S phase is accompanied by a reduction in transformability. These results indicate that resting B cells are highly susceptible to transformation, and that with in vitro activation into the cell cycle B cells become resistant to EBV transformation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028939      PMCID: PMC1453228     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

1.  Epstein-Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoic cell lines and in the blood of patients with infectious mononucleosis.

Authors:  M F Greaves; G Brown
Journal:  Clin Immunol Immunopathol       Date:  1975-03

2.  Induction of Epstein-Barr virus-associated nuclear antigen during in vitro transformation of human lymphoid cells.

Authors:  W Leibold; T D Flanagan; J Menezes; G Klein
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

3.  EB virus-induced B lymphocyte cell lines producing specific antibody.

Authors:  M Steinitz; G Klein; S Koskimies; O Makel
Journal:  Nature       Date:  1977-09-29       Impact factor: 49.962

4.  Efficiency of transformation of lymphocytes by Epstein-Barr virus.

Authors:  E Henderson; G Miller; J Robinson; L Heston
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

5.  Identification of the target cells in human B lymphocytes for transformation by Epstein-Barr virus.

Authors:  T Katsuki; Y Hinuma; N Yamamoto; T Abo; K Kumagai
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

6.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

Authors:  G Henle; W Henle; V Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1968-01       Impact factor: 11.205

7.  Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody.

Authors:  A W Boyd; K C Anderson; A S Freedman; D C Fisher; B Slaughenhoupt; S F Schlossman; L M Nadler
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

8.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

9.  Principles of blood separation and component extraction in a disposable continuous-flow single-stage channel.

Authors:  J P Hester; R M Kellogg; A P Mulzet; V R Kruger; K B McCredie; E J Freireich
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

10.  Quantitative assays for detection of residual T cells of T-depleted human marrow.

Authors:  P J Martin; J A Hansen
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

View more
  4 in total

Review 1.  Generation of stable human autoantibody-secreting B cell hybridomas.

Authors:  N Chiorazzi
Journal:  Mol Biol Rep       Date:  1992-05       Impact factor: 2.316

2.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

3.  Negative modulation of Epstein-Barr virus episomes by a human B-cell growth factor.

Authors:  J Morgan; A Roome; A Maizel; S Sharma
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry.

Authors:  G Inghirami; M Nakamura; J E Balow; A L Notkins; P Casali
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.